Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IL3RA | SNV | Missense_Mutation | rs760003424 | c.914N>A | p.Arg305Gln | p.R305Q | P26951 | protein_coding | tolerated(0.43) | benign(0.132) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
IL3RA | SNV | Missense_Mutation | | c.628N>G | p.Pro210Ala | p.P210A | P26951 | protein_coding | tolerated(0.44) | probably_damaging(0.998) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
IL3RA | SNV | Missense_Mutation | rs766258222 | c.328C>G | p.Leu110Val | p.L110V | P26951 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
IL3RA | SNV | Missense_Mutation | rs753774133 | c.146A>G | p.Asp49Gly | p.D49G | P26951 | protein_coding | tolerated(0.44) | benign(0) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
IL3RA | SNV | Missense_Mutation | novel | c.221C>A | p.Ser74Tyr | p.S74Y | P26951 | protein_coding | tolerated(0.07) | possibly_damaging(0.907) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IL3RA | SNV | Missense_Mutation | novel | c.879N>G | p.Cys293Trp | p.C293W | P26951 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-C5-A2LY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
IL3RA | SNV | Missense_Mutation | | c.81N>G | p.Ile27Met | p.I27M | P26951 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
IL3RA | SNV | Missense_Mutation | | c.886N>C | p.Glu296Gln | p.E296Q | P26951 | protein_coding | tolerated(0.11) | benign(0.425) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
IL3RA | SNV | Missense_Mutation | novel | c.35N>A | p.Ala12Asp | p.A12D | P26951 | protein_coding | deleterious(0.01) | benign(0.129) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IL3RA | SNV | Missense_Mutation | novel | c.818N>C | p.Arg273Thr | p.R273T | P26951 | protein_coding | deleterious(0.01) | possibly_damaging(0.766) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | UCART123 | | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Anti-CD123 CAR-T treatment | | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Tagraxofusp | TAGRAXOFUSP | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes | | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | CART-123 cells | | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | CART123 cells | | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | IM23 | | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Anti-CD123 CAR-T cells | | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Anti-CD123-CAR-transduced T cells | | |
3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells | | |